Inebilizumab for neuromyelitis optica spectrum disorder in Italy: a budget impact model.

Carlo LazzaroNicola Amedeo MazzantiSilvia RossiFabio Parazzini

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

Inebilizumab reduces the INHS expenditure for NMOSD drugs. Future research should explore the cost-effectiveness of inebilizumab vs other NMOSD-targeting drugs in Italy.

Keyphrases

spectrum disorder
current status
cancer therapy
drug induced
drug delivery